Essure® is a form of female sterilisation which involves the hysteroscopic insertion of flexible micro-inserts into the proximal section of the fallopian tubes and is undertaken without general anaesthesia.
Filter documents Clear search
The CEU supports the self administration of Sayana Press® because of its potential benefits to women and services. It offers women greater choice and more autonomy over their contraception and fertility.
FSRH CEU Statement: CEU response to published study: Chlamydia screening for pregnant women aged 16–25 years attending an antenatal service (August 2015)
The BJOG: An International Journal of Obstetrics and Gynaecology today published an Australian study that considers the cost effectiveness of routine screening for Chlamydia trachomatis in all pregnant women aged 16 to 25 years.
The recent article in the Telegraph newspaper has highlighted the complex issues surrounding sexual activity in young women in the UK. Whilst it is true that the legal age of consent to sexual activity in the UK is 16 years, surveys suggest that almost one in three young people will have had sexual intercourse by this age.
Gliomas are glial cell tumours which can occur in the spinal cord or the brain and are the most common type of brain tumour. They vary greatly in their likely rate of growth, differentiation and prognosis. Glioblastoma multiforme is the most common and most aggressive primary brain tumour.
The Faculty of Sexual and Reproductive Healthcare (FSRH) has been made aware that the Reflexions® flat spring diaphragm range, manufactured by Williams Medical, is being discontinued in the UK.
FSRH CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015)
Progestogen-only injectable contraception is widely used across the world and is particularly popular in resource poor countries with a high incidence of HIV infection e.g. in sub-Saharan Africa. It is clearly important therefore to establish whether there is any relationship between the use of injectable contraception and increased risk of HIV acquisition.
CEU Statement Vasectomy and prostate cancer Jul 2014
Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.
An article published in the British Medical Journal (BMJ) in November 2013, questioned whether women with HIV, or at high risk of contracting HIV, should use progestogen-containing contraceptives.